Associate Professor, Department of Medicinal Chemistry; Assistant Director, Pharmaceutical Bioengineering Extension Program
PhD, University of Washington; Master of Science and Bachelor of Science, University of California, Riverside
- Development of a "humanized" Cyp4b1 knockout mouse
- Function of "orphan" CYP4 cells in health and disease
- Utility of embryonic stem (ES) cells as a source of human hepatocytes
Dr. Kelly earned his PhD in Biochemistry from the University of Washington in the laboratory of Dr. Richard Palmiter, developing transgenic and knockout mouse models to study the function of the metal-binding protein metallothionein. Following a postdoctoral fellowship in molecular toxicology at the UW Department of Environmental Health with Dave Eaton, he ventured into Biotech, managing the Preclinical Bioanalytics group at Targeted Genetics Corporation, evaluating the safety and efficacy of gene therapies for diseases such as cystic fibrosis, rheumatoid arthritis and hemophilias.
Upon his return to academia, his research interests have stayed within the realm of preclinical biology. His lab works on developing novel models to study normal human physiology and disease states, with a particular focus on cytochrome P450 enzymes and their role in endobiotic/xenobiotic metabolism. Specific areas include studying the heritable ocular disease, Bietti's Crystalline Dystrophy, derivation of metabolically active hepatocytes from embryonic stem cells and development of a human kidney "organ-on-a-chip." Currently, he holds the position of associate professor in the Department of Pharmaceutics, and also serves as assistant director of the Pharmaceutical Bioengineering Extension Program.